Wesure Globaltech in the US: Still a Funded Option, Not a Group Funding Engine

The main article framed the group around Ayalon's capital test, but the US platform isolates a different question: can the new growth layer already return capital to the group, or is it still consuming capital before earnings proof arrives. The first-quarter filing leans clearly toward the second answer. The loss in the Other category is mainly attributed to the US companies, the UBIC path may require another USD 6-10 million of capital, and the Hourly/MDS acquisition currently sits on NIS 84.959 million of intangible assets plus NIS 18.908 million of goodwill under provisional accounting. That does not mean the US move has no value: the combination of payroll, MGA agencies and Workers' Compensation insurance can still become a strategic asset. But from a capital-allocation perspective, Wesure Globaltech is still showing a funded US option, not a cash source that finances the rest of the group. The next proof points are a binding UBIC agreement, the funding source for the possible capital injection, and the first commercial disclosure showing that the US platform is starting to return money rather than only build structure.

The loss is already in the filing, the contribution is not

The important first-quarter signal does not come from the UBIC headline. It comes from the Other line. The Other category recorded a NIS 5.060 million loss in the first three months of 2026, compared with a NIS 808 thousand profit in the comparable quarter. The explanation is short but material: the move to a loss was mainly due to losses in companies operating in the US.

That is a small disclosure with a large analytical consequence. The US platform already has operations, payroll companies, MGA agencies, a strategic partner and a business frame aimed at Workers' Compensation. Still, in the consolidated results, the current quantitative expression is a loss in Other, not a contribution that offsets capital needs. For an insurance and financial holding group, early losses in a growth platform can be normal. They are not free upside when the group is also evaluating the acquisition of a US insurance carrier that may require regulatory capital.

The annual investor presentation helps explain management's framing. It presents the US move as a synergy between payroll and insurance, with operations in most US states after the Hourly transaction and a potential fit between payroll calculation and Workers' Compensation premiums. That explains why management sees a platform rather than only a financial investment. In the first quarter, however, the gap between the strategic story and the financial report is still visible: the option exists, the economics are not yet proven.

UBIC shifts the discussion from purchase price to capital need

UBIC's headline purchase price looks small: USD 1.2 million if all shareholders tender, or a partial purchase mechanism of up to about USD 980 thousand multiplied by the acceptance rate. By May 18, 2026, full acceptance had not been received, but 92% of UBIC shareholders had accepted the sale. That keeps the partial path alive, but it does not make the transaction closed.

The number that should lead the discussion is not the share price. If the MOU matures into a transaction, the company may need to inject another USD 6-10 million into UBIC to meet regulatory requirements. There are also additional conditions: due diligence, regulatory approvals, a final purchase agreement, understandings with UBIC Tier 2 capital-note holders, corporate approvals and licenses required by law. After the USICOA path was stopped because discussions ran beyond the MOU timetable and the parties failed to agree, including on interim management, the new MOU cannot be read as if a US carrier is already inside the group.

The USD 300 thousand capital note adds an intermediate layer. It carries 10% annual interest, matures on July 1, 2030, and conversion could result in an approximately 20% UBIC holding, subject to regulatory approvals. In parallel, if the full or partial acquisition is not completed, the company is negotiating to acquire the rights held by UBIC's founder and CEO and his family, which represent about 46% of UBIC shares and URS rights. That leaves several paths open, but they all return to the same point: the company needs a capital plan, not only a low entry price.

Hourly and MDS are assets to justify, not earnings already delivered

The Hourly and MDS business-combination note sharpens the quality of the US asset. No cash consideration was paid in the transaction. Instead, WUS shares were issued to the former shareholders of Hourly and MDS. After the transaction, Wesure Globaltech's fully diluted holding in WUS fell to 39.5%, but it remained the controlling shareholder and appoints a majority of the board. WUS therefore remains consolidated, even though part of the future economics now belongs to partners and other shareholders.

The accounting measurement is still provisional. The identified Hourly and MDS assets include NIS 84.959 million of intangible assets, alongside NIS 18.908 million of goodwill. Within the intangible assets, most of the value is attributed to Hourly technology at NIS 68.316 million with a 10-year amortization period, Hourly customer relationships of NIS 13.556 million with a 4-year period, a trademark of NIS 1.762 million with a 4-year period, and MDS customer relationships of NIS 1.325 million with an 8-year period. The external appraiser reviewed the valuation as of December 31, 2025 and determined that there was no material adverse change versus the fair value estimated at the transaction date, but final adjustments may still be made up to 12 months after the acquisition date.

This is where accounting does not prove the economics. Intangible assets and goodwill can be a good platform base if they turn into revenue, premiums, customer retention or underwriting profitability. For now, they mostly show the economic price of the expansion: another value layer that has to be justified later, while the current quarter already shows a loss in Other. The question is not whether Hourly and MDS have strategic logic. It is when that logic appears in metrics that do not depend on valuation assumptions.

The next read depends on commercial disclosure and funding source

The current US read should remain conservative: there is a platform, there are partners, and there is a possible route to a US carrier, but there is still no proof that the activity funds itself. The counterpoint is fair: the company had significant solo cash of about NIS 372 million at the end of March 2026, so a UBIC injection does not look like immediate liquidity pressure. But that does not make it costless. Every dollar directed to strengthening a US insurance company is a dollar not directed to distributions, debt reduction, strengthening the Israeli insurance engines or developing other group arms.

The next disclosure that would change the conclusion is one that connects the US to results: premiums, revenue, customer base, loss ratio or another metric showing that the payroll and Workers' Compensation combination is working in practice. Until that arrives, UBIC and the Hourly/MDS valuation should be read mainly through capital allocation. If a binding transaction is signed with a defined injection and clear funding source, the risk becomes more measurable. If the capital requirement grows without parallel commercial disclosure, the US remains a more expensive option, even if the option itself is strategically interesting.